Inhixa

Enoxaparin Sodium, the active ingredient in Inhixa, is a low molecular weight heparin presented as a sterile solution for subcutaneous administration. It is used to prevent and treat thromboembolic disorders in adult patients undergoing surgery, dialysis, or at risk of clot formation.

GNH USA supplies Inhixa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide.

Enoxaparin Sodium is indicated for anticoagulation in several clinical settings related to venous thromboembolism and dialysis.

- Deep vein thrombosis prophylaxis: prevents clot formation in postoperative orthopedic and general surgery patients. - Acute deep vein thrombosis treatment: facilitates clot resolution and reduces risk of embolization. - Pulmonary embolism treatment: provides anticoagulation to limit clot propagation. - Hemodialysis circuit anticoagulation: maintains patency of extracorporeal circuits during dialysis. - Acute coronary syndrome (unstable angina/NSTEMI): reduces risk of recurrent ischemic events.

Enoxaparin Sodium may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Injection site bruising or pain. - Minor bleeding such as gum or nosebleeds. - Elevated liver enzymes. - Nausea. - Mild thrombocytopenia.

Serious or Rare Side Effects: - Major hemorrhage (intracranial or gastrointestinal). - Heparin‑induced thrombocytopenia (HIT). - Spinal or epidural hematoma. - Anaphylactic allergic reactions. - Severe thrombocytopenia with bleeding. - Rare liver failure.

When using Enoxaparin Sodium, clinicians should consider several safety measures.

- Renal impairment: adjust dose or monitor anti‑Xa levels. - History of heparin‑induced thrombocytopenia: avoid use. - Recent surgery or trauma: assess bleeding risk. - Concomitant antiplatelet or anticoagulant therapy: increase monitoring. - Pregnancy and lactation: use only if benefit outweighs risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Enoxaparin Sodium can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Concurrent use with other anticoagulants (e.g., warfarin, direct oral anticoagulants) – high risk of severe bleeding. - Use with systemic thrombolytics – increased hemorrhagic risk. - Combination with non‑steroidal anti‑inflammatory drugs (NSAIDs) – potentiate bleeding.

Moderate Interactions (Monitor Closely): - Antiplatelet agents (e.g., clopidogrel, aspirin) – monitor for bleeding. - Selective serotonin reuptake inhibitors (SSRIs) – may increase bleeding tendency. - ACE inhibitors – possible additive effect on platelet function. - Certain antibiotics (e.g., vancomycin) – monitor renal function and anti‑Xa levels.